# Tirzepatide – 60mg/vial (Research Use Only)

## Overview

**Independent lab result · batch PTW-Tirz-2608-001**

Tirzepatide 60mg. Tested by Janoshik Analytical (task #239838), analysis conducted 7 Oct 2026. The sample was pulled from our own stock, submitted and paid for by Portal to Wellness, and the report names us as the client.

- Identity: tirzepatide, confirmed by blind test
- Measured content: 65.05 mg per vial (labelled 60 mg)
- Purity: 99.740% (HPLC)

[View and verify the full report on Janoshik’s site →](https://verify.janoshik.com/tests/239838-Tirzepatide_60mg_IBKT34GIRCJT)

This result applies to batch PTW-Tirz-2608-001, the batch currently shipping. The batch number is printed on the vial label. See all published results on our [Lab Testing & Verification](https://portaltowellness.net/lab-verification-quality-testing/) page.

Backed by the Research [Read: SURMOUNT-MMO Trial Explained →](https://portaltowellness.net/research/surmount-mmo-trial-tirzepatide-mortality/)

Tirzepatide is a synthetic dual-agonist peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. Its dual-receptor mechanism provides a pharmacological tool for studying complementary incretin signaling pathways simultaneously, and it has been extensively examined in published preclinical and clinical pharmacology literature focused on metabolic, cardiovascular, and hepatic biology.

## What It Is

Tirzepatide is a 39-amino acid synthetic peptide designed as a dual agonist at the GIP receptor (GIPR) and GLP-1 receptor (GLP-1R). It is based on the native GIP sequence with modifications enabling GLP-1 receptor co-activation and a C20 fatty diacid chain at lysine-26 for extended half-life via albumin binding. Molecular formula: C₂₂₅H₃₄₈N₄₈O₆₈. Molecular weight: approximately 4,813.45 Da. CAS number: 2023788-19-2.

## Research Spotlight

The research profile of tirzepatide is defined by its dual-receptor mechanism, which activates both the GIP and GLP-1 pathways — systems with distinct but overlapping roles in postprandial glucose regulation, insulin secretion, glucagon suppression, and energy homeostasis. Published preclinical research has investigated tirzepatide’s differential effects on adipose tissue (GIP receptor-mediated) versus appetite and gastric motility (GLP-1 receptor-mediated), providing mechanistic data for comparative metabolic studies. Cardiovascular research has examined lipid profiles, myocardial inflammation markers, and vascular remodeling parameters in animal models. Comparative pharmacology studies have evaluated tirzepatide against semaglutide and other GLP-1 agonists to quantify receptor binding affinity and tissue-specific signaling differences. Additional published research has explored renal and hepatic biomarker responses in NASH and kidney function models, as well as skeletal muscle protein synthesis pathways in relevant animal preparations.

## Key Research Applications

- Dual GIP and GLP-1 receptor co-activation and downstream signaling studies
- Comparative receptor pharmacology vs. GLP-1 mono-agonist compounds
- Pancreatic beta-cell insulin secretion and glucose-dependent insulinotropic modeling
- Adipose tissue biology, lipolysis, and body composition research
- Appetite, satiety signaling, and central GLP-1 pathway investigations
- Cardiovascular risk marker modulation and cardiac inflammation research
- NASH, hepatic steatosis, and renal function marker studies
- Skeletal muscle protein synthesis and lean mass preservation modeling
- Long-acting fatty acid-conjugated peptide pharmacokinetics
- Incretin receptor selectivity and synergy research

*For laboratory research use only. Not intended for human or veterinary use, medical diagnosis, treatment, or prevention of any disease or condition. This product has not been evaluated by the FDA or any regulatory agency. Must be handled by qualified research personnel in a compliant laboratory setting.*

Not sure which compounds fit your research? [Browse the Research Hub →](https://portaltowellness.net/research/)

## Frequently Asked Questions — Tirzepatide

### What makes Tirzepatide a dual agonist and why does it matter?

Tirzepatide binds both the GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptors. In the published literature, GLP-1 receptor agonism is associated with delayed gastric emptying and altered satiety signalling, while GIP receptor agonism is associated with glucose-dependent insulin secretion and a possible role in adipose tissue metabolism. Studies of the dual mechanism report metabolic endpoints distinct from those of single-receptor GLP-1 agonists. These findings come from clinical trials of pharmaceutical-grade tirzepatide conducted under medical supervision and are provided as background on the molecule.

### How does Tirzepatide differ from Semaglutide mechanistically?

Semaglutide is a single-receptor GLP-1 agonist. Tirzepatide binds both the GLP-1 and the GIP receptor, so the two compounds engage different receptor sets. The published trial programmes for each measured body-weight and HbA1c endpoints, and comparative analyses exist in that literature. Portal to Wellness does not reproduce figures from those trials on product pages: they describe pharmaceutical-grade material given to people under medical supervision, which is not what is sold here.

### What has published research examined for Tirzepatide?

The SURPASS and SURMOUNT clinical trial programs evaluated Tirzepatide across metabolic and body-composition endpoints, and comparative studies have measured its receptor binding and tissue-specific signaling against other incretin compounds. PTW Tirzepatide is supplied for laboratory research purposes only and is not intended for human use.

### What purity standard applies to this tirzepatide?

The supplier specification is ≥98% purity. Portal to Wellness supplies it for laboratory research use only.

### What is the molecular structure of Tirzepatide compared to native GIP?

Tirzepatide is a 39-amino-acid synthetic peptide based on the native GIP sequence, modified to incorporate GLP-1 receptor affinity. A C20 fatty diacid chain is attached via a linker to enable albumin binding and extend the half-life to approximately 5 days.

### Related Research (Educational)

- [Body Recomposition with GLP-1 Peptides: What the Research Shows](https://portaltowellness.net/research/body-recomposition-glp1-research/)
- [Muscle Preservation During Caloric Restriction: Research Compound Insights](https://portaltowellness.net/research/muscle-preservation-caloric-restriction-research/)
- [Visceral Fat and Metabolic Health: What Researchers Are Studying](https://portaltowellness.net/research/visceral-fat-metabolic-health-research/)

Research Library

- [Injectable vs. Oral GLP-1: What Researchers Need to Know](https://portaltowellness.net/research/injectable-vs-oral-glp1-what-researchers-need-to-know/)
- [GLP-1 Receptor Agonists and Biological Aging: What the Research Shows](https://portaltowellness.net/research/glp1-biological-aging-epigenetic-research/)
- [Preserving Lean Mass During GLP-1 Research: What the SEMALEAN Data Showed](https://portaltowellness.net/research/preserving-lean-mass-glp-1-semalean-data/)
- [Regulatory Pathway Labels Explained: Branded, Generic, Compounded and RUO →](https://portaltowellness.net/research/regulatory-pathway-labels-explained/)
- [SURMOUNT-MMO Trial Explained](https://portaltowellness.net/research/surmount-mmo-trial-tirzepatide-mortality/)
- [GLP-1 Frailty Risk in Older Adults](https://portaltowellness.net/research/glp-1-frailty-risk-older-adults/)
- [GLP-1 Dosing Errors: Telehealth Data](https://portaltowellness.net/research/glp-1-dosing-errors-telehealth/)
- [What Determines Regulatory Status](https://portaltowellness.net/research/what-determines-regulatory-status/)
- [GLP-1s and Eating Disorder Risk](https://portaltowellness.net/research/glp-1-eating-disorder-risk/)
- [GLP-1 vs. Bariatric Surgery in Teens: What New Data Shows](https://portaltowellness.net/research/glp-1-bariatric-surgery-teens/)
- [FDA Warning Letters Hit GLP-1 Telehealth Marketing: What the 2026 Crackdown Means](https://portaltowellness.net/research/fda-warning-letters-glp1-telehealth-crackdown/)
- [GLP-1 Prior Authorization Data](https://portaltowellness.net/research/glp-1-prior-authorization-data/)
- [Compounded Peptide vs Research Peptide](https://portaltowellness.net/research/compounded-peptide-vs-research-peptide/)
- [Biomarkers vs Clinical Outcomes in Research](https://portaltowellness.net/research/biomarkers-vs-clinical-outcomes-research/)
- [Biomarkers vs Clinical Outcomes in Research](https://portaltowellness.net/research/biomarkers-vs-clinical-outcomes-research/)
- [Obesity Subtype, Tirzepatide Response](https://portaltowellness.net/research/obesity-subtype-tirzepatide-response/)
- [GLP-1 Additives: What a New JAMA Study Found](https://portaltowellness.net/research/glp-1-additives-compounding-study/)
- [GLP-1 Cancer Risk: What Trials Show](https://portaltowellness.net/research/glp-1-cancer-risk-what-trials-show/)
- [GLP-1 Mood Research: What Trials Show](https://portaltowellness.net/research/glp-1-mood-research-what-trials-show/)
- [Real-World GLP-1 Outcomes vs Trial Results](https://portaltowellness.net/research/real-world-glp-1-outcomes-vs-trials/)
- [GLP-1 Receptor Agonists: Mechanisms in the Literature](https://portaltowellness.net/research/glp-1-health-benefits-explained/)

---

Source: https://portaltowellness.net/shop/tirzepatide-60mg/
Research use only. Terms: https://portaltowellness.net/research-use-only/